Equities Analysts Offer Predictions for DAWN FY2029 Earnings

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) – Stock analysts at HC Wainwright dropped their FY2029 earnings per share (EPS) estimates for Day One Biopharmaceuticals in a research note issued on Wednesday, November 5th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn $0.88 per share for the year, down from their previous forecast of $1.01. HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($0.72) per share.

DAWN has been the topic of a number of other reports. Zacks Research raised Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, October 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research note on Thursday, October 30th. Needham & Company LLC reduced their target price on shares of Day One Biopharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a report on Wednesday, August 6th. Finally, Piper Sandler increased their price target on Day One Biopharmaceuticals from $25.00 to $26.00 and gave the stock an “overweight” rating in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Day One Biopharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $25.43.

Day One Biopharmaceuticals Price Performance

Day One Biopharmaceuticals stock opened at $9.14 on Thursday. Day One Biopharmaceuticals has a 1-year low of $5.64 and a 1-year high of $16.76. The stock has a market capitalization of $936.21 million, a price-to-earnings ratio of -6.01 and a beta of -1.25. The business has a fifty day moving average price of $7.31 and a 200-day moving average price of $6.95.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.09. The business had revenue of $39.80 million for the quarter, compared to the consensus estimate of $38.20 million. Day One Biopharmaceuticals had a negative return on equity of 31.55% and a negative net margin of 113.53%.The business’s revenue was down 57.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.38 EPS.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Several hedge funds have recently bought and sold shares of DAWN. Wealth Enhancement Advisory Services LLC bought a new position in shares of Day One Biopharmaceuticals in the 1st quarter valued at approximately $88,000. Dynamic Technology Lab Private Ltd acquired a new position in Day One Biopharmaceuticals in the 1st quarter valued at approximately $384,000. Ieq Capital LLC bought a new position in Day One Biopharmaceuticals in the first quarter worth $294,000. Allianz Asset Management GmbH acquired a new position in Day One Biopharmaceuticals in the first quarter worth about $198,000. Finally, Parkman Healthcare Partners LLC lifted its position in shares of Day One Biopharmaceuticals by 4.3% during the 1st quarter. Parkman Healthcare Partners LLC now owns 1,043,162 shares of the company’s stock worth $8,272,000 after buying an additional 42,688 shares during the period. Institutional investors and hedge funds own 87.95% of the company’s stock.

Insider Buying and Selling

In other news, insider Lauren Merendino sold 3,766 shares of the company’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $6.77, for a total value of $25,495.82. Following the completion of the sale, the insider directly owned 41,931 shares in the company, valued at $283,872.87. This represents a 8.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Charles N. York II sold 4,106 shares of the company’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $6.77, for a total transaction of $27,797.62. Following the completion of the sale, the chief financial officer directly owned 278,000 shares of the company’s stock, valued at $1,882,060. This represents a 1.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 28,295 shares of company stock valued at $191,557. 6.20% of the stock is currently owned by company insiders.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.